Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer


Study Number
70518
Purpose

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.

Full Title

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy

ClinicalTrials.Gov ID
NCT03547973

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.